The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Pharmacogenetics of warfarin: current status and future challenges
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., et al. (2001) · Nature Genetics · doi:10.1038/86882 · Cited by 2,162
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804
Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
Rieder, M. J., Reiner, A. P., Gage, B. F., Nickerson, D. A., Eby, C. S., McLeod, H. L., Blough, D. K., Thummel, K. E., Veenstra, D. L., & Rettie, A. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044503 · Cited by 1,399
Aithal, G. P., Day, C. P., Kesteven, P. J., & Daly, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)04474-2 · Cited by 1,243
Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2
Rost, S., Fregin, A., Ivaskevicius, V., Conzelmann, E., Hörtnagel, K., Pelz, H.-J., Lappegard, K., Seifried, E., Scharrer, I., Tuddenham, E. G. D., et al. (2004) · Nature · doi:10.1038/nature02214 · Cited by 1,134
Higashi, M. K. (2002) · JAMA · doi:10.1001/jama.287.13.1690 · Cited by 1,048
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Moore, L. B., Goodwin, B., Jones, S. A., Wisely, G. B., Serabjit-Singh, C. J., Willson, T. M., Collins, J. L., & Kliewer, S. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.130155097 · Cited by 947
Sconce, E. A., Khan, T. I., Wynne, H. A., Avery, P., Monkhouse, L., King, B. P., Wood, P., Kesteven, P., Daly, A. K., & Kamali, F. (2005) · Blood · doi:10.1182/blood-2005-03-1108 · Cited by 947
Nuclear Receptor Response Elements Mediate Induction of Intestinal MDR1 by Rifampin
Geick, A., Eichelbaum, M., & Burk, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010173200 · Cited by 848
Human P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Linkins, L.-A., Choi, P. T., & Douketis, J. D. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-11-200312020-00007 · Cited by 764
Identification of the gene for vitamin K epoxide reductase
Li, T., Chang, C.-Y., Jin, D.-Y., Lin, P.-J., Khvorova, A., & Stafford, D. W. (2004) · Nature · doi:10.1038/nature02254 · Cited by 707
D'Andrea, G., D'Ambrosio, R. L., Di Perna, P., Chetta, M., Santacroce, R., Brancaccio, V., Grandone, E., & Margaglione, M. (2005) · Blood · doi:10.1182/blood-2004-06-2111 · Cited by 699
Rettie, A. E., Korzekwa, K. R., Kunze, K. L., Lawrence, R. F., Eddy, A. C., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., & Trager, W. F. (1992) · Chemical Research in Toxicology · doi:10.1021/tx00025a009 · Cited by 601
The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin
Fihn, S. D., Callahan, C. M., Martin, D. C., McDonell, M. B., Henikoff, J. G., White, R. H., & National Consortium of Anticoagulation Clinics* (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-11-199606010-00004 · Cited by 555
Yuan, H.-Y., Chen, J.-J., Lee, M. T. M., Wung, J.-C., Chen, Y.-F., Charng, M.-J., Lu, M.-J., Hung, C.-R., Wei, C.-Y., Chen, C.-H., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi180 · Cited by 486
Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9
Rettie, A. E., Wienkers, L. C., Gonzalez, F. J., Trager, W. F., & Korzekwa, K. R. (1994) · Pharmacogenetics · doi:10.1097/00008571-199402000-00005 · Cited by 485
EPOXIDE HYDROLASES: Mechanisms, Inhibitor Designs, and Biological Roles
Morisseau, C., & Hammock, B. D. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095920 · Cited by 479
Clinical consequences of cytochrome P450 2C9 polymorphisms
KIRCHHEINER, J., & BROCKMOLLER, J. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2004.08.009 · Cited by 474
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
Wadelius, M., Chen, L. Y., Downes, K., Ghori, J., Hunt, S., Eriksson, N., Wallerman, O., Melhus, H., Wadelius, C., Bentley, D., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500313 · Cited by 468
Self-citationKroetz, D. L., Pauli-Magnus, C., Hodges, L. M., Huang, C. C., Kawamoto, M., Johns, S. J., Stryke, D., Ferrin, T. E., DeYoung, J., Taylor, T., et al. (2003) · Pharmacogenetics · doi:10.1097/00008571-200308000-00006 · Cited by 429
Taube, J., Halsall, D., & Baglin, T. (2000) · Blood · doi:10.1182/blood.v96.5.1816 · Cited by 392
Effect of grapefruit juice on digoxin pharmacokinetics in humans
Becquemont, L., Verstuyft, C., Kerb, R., Brinkmann, U., Lebot, M., Jaillon, P., & Funck‐Brentano, C. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(01)17221-8 · Cited by 387
Takahashi, H., Wilkinson, G. R., Nutescu, E. A., Morita, T., Ritchie, M. D., Scordo, M. G., Pengo, V., Barban, M., Padrini, R., Ieiri, I., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000184955.08453.a8 · Cited by 376
Sanderson, S., Emery, J., & Higgins, J. (2005) · Genetics in Medicine · doi:10.1097/01.gim.0000153664.65759.cf · Cited by 363
Bodin, L. (2005) · Blood · doi:10.1182/blood-2005-01-0341 · Cited by 360
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., Deykin, D., & Brandt, J. T. (1998) · Chest · doi:10.1378/chest.114.5_supplement.445s · Cited by 349
Keavney, B., McKenzie, C., Parish, S., Palmer, A., Clark, S., Youngman, L., Delépine, M., Lathrop, M., Peto, R., & Collins, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)82009-7 · Cited by 345
Scordo, M. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.129321 · Cited by 344
Pharmacogenetics of Warfarin Elimination and Its Clinical Implications
Takahashi, H., & Echizen, H. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140080-00003 · Cited by 312
Warfarin-associated hemorrhage and cerebral amyloid angiopathy: A genetic and pathologic study
Rosand, J., Hylek, E. M., O’Donnell, H. C., & Greenberg, S. M. (2000) · Neurology · doi:10.1212/wnl.55.7.947 · Cited by 305
Genetic association between sensitivity to warfarin and expression of CYP2C9*3
Steward, D. J., Haining, R. L., Henne, K. R., Davis, G., Rushmore, T. H., Trager, W. F., & Rettie, A. E. (1997) · Pharmacogenetics · doi:10.1097/00008571-199710000-00004 · Cited by 303
Furuya, H., Fernandez-Salguero, P., Gregory, W., Taber, H., Steward, A., Gonzalez, F. J., & Idle, J. R. (1995) · Pharmacogenetics · doi:10.1097/00008571-199512000-00008 · Cited by 278
AQUILANTE, C., LANGAEE, T., LOPEZ, L., YARANDI, H., TROMBERG, J., MOHUCZY, D., GASTON, K., WADDELL, C., CHIRICO, M., & JOHNSON, J. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.011 · Cited by 266
Crespi, C. L., & Miller, V. P. (1997) · Pharmacogenetics · doi:10.1097/00008571-199706000-00005 · Cited by 264
Interindividual variability in sensitivity to warfarin-Nature or nurture?
Loebstein, R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.117444 · Cited by 260
Geisen, C., Watzka, M., Sittinger, K., Steffens, M., Daugela, L., Seifried, E., Müller, C. R., Wienker, T. F., & Oldenburg, J. (2005) · Thrombosis and Haemostasis · doi:10.1160/th05-04-0290 · Cited by 259
Aguilar, M. I., & Hart, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001927.pub2 · Cited by 252
Haining, R. L., Hunter, A. P., Veronese, M. E., Trager, W. F., & Rettie, A. E. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0414 · Cited by 249
NAD(P)H:Quinone Oxidoreductase 1 (NQO1, DT-Diaphorase), Functions and Pharmacogenetics
Ross, D., & Siegel, D. (2004) · Methods in Enzymology · doi:10.1016/s0076-6879(04)82008-1 · Cited by 245
Genetic Modulation of Oral Anticoagulation with Warfarin
Colaizzo, D., D’Andrea, G., Brancaccio, V., Ciampa, A., Grandone, E., Di Minno, G., & Margaglione, M. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614114 · Cited by 233
Chen, Y., Ferguson, S. S., Negishi, M., & Goldstein, J. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.058818 · Cited by 224
DAHLBÄCK, B. (2005) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01444.x · Cited by 211
Hillman, M. A., Wilke, R. A., Yale, S. H., Vidaillet, H. J., Caldwell, M. D., Glurich, I., Berg, R. L., Schmelzer, J., & Burmester, J. K. (2005) · Clinical Medicine & Research · doi:10.3121/cmr.3.3.137 · Cited by 196
Pharmacogenetics of oral anticoagulants
Daly, A. K., & King, B. P. (2003) · Pharmacogenetics · doi:10.1097/00008571-200305000-00002 · Cited by 195
Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors
Wadelius, M., Sörlin, K., Wallerman, O., Karlsson, J., Yue, Q.-Y., Magnusson, P. K. E., Wadelius, C., & Melhus, H. (2004) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500220 · Cited by 191
Self-citationWarfarin therapy: evolving strategies in anticoagulation.
Horton, J. D., & Bushwick, B. M. (1999) · PubMed · Cited by 190
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype
Voora, D., Eby, C., Linder, M. W., Milligan, P. E., Bukaveckas, B. L., McLeod, H. L., Maloney, W., Clohisy, J., Burnett, S. R., Grosso, L., et al. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0542 · Cited by 189
The physiology of vitamin K nutriture and vitamin K‐dependent protein function in atherosclerosis
Berkner, K. L., & Runge, K. W. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00968.x · Cited by 185
Takahashi, H., Kashima, T., Nomizo, Y., Muramoto, N., Shimizu, T., Nasu, K., Kubota, T., Kimura, S., & Echizen, H. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90103-5 · Cited by 183
EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM
Huang, W., Lin, Y. S., McConn, D. J., Calamia, J. C., Totah, R. A., Isoherranen, N., Glodowski, M., & Thummel, K. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.001313 · Cited by 175
Clinical relevance of genetic polymorphisms in the human CYP2C9 gene
Schwarz, U. I. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.33.s2.6.x · Cited by 170
Assénat, E., Gerbal‐Chaloin, S., Larrey, D. G., Saric, J., Fabre, J., Maurel, P., Vilarem, M., & Pascussi, J. (2004) · Hepatology · doi:10.1002/hep.20387 · Cited by 165
Shikata, E., Ieiri, I., Ishiguro, S., Aono, H., Inoue, K., Koide, T., Ohgi, S., & Otsubo, K. (2004) · Blood · doi:10.1182/blood-2003-09-3043 · Cited by 159
Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests
ANDERSSON, T., Flockhart, D. A., Goldstein, D. A., Huang, S. M., Kroetz, D. L., Milos, P. M., Ratain, M. J., & Thummel, K. E. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.08.013 · Cited by 153
Transport of Vitamin K to Bone in Humans
Kohlmeier, M., Salomon, A., Saupe, J., & Shearer, M. J. (1996) · Journal of Nutrition · doi:10.1093/jn/126.suppl_4.1192s · Cited by 151
Warfarin Withdrawal: Pharmacokinetic-Pharmacodynamic Considerations
Palareti, G., & Legnani, C. (1996) · Clinical Pharmacokinetics · doi:10.2165/00003088-199630040-00003 · Cited by 148
Lee, S. M. L., NG, S., Oldenburg, J., CHONG, P., Rost, S., GUO, J., Yap, H., RANKIN, S., Khor, H. T., YEO, T., et al. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.11.006 · Cited by 147
Vitamin K‐Dependent Carboxylation
Berkner, K. L. (2008) · Vitamins and hormones · doi:10.1016/s0083-6729(07)00007-6 · Cited by 145
Aguilar, M. I., & Hart, R. G. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001925.pub2 · Cited by 139
Plasma lipoproteins as carriers of phylloquinone (vitamin K1) in humans
Lamon‐Fava, S., Sadowski, J., Davidson, K. W., O’Brien, M., McNamara, J., & Schaefer, E. J. (1998) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/67.6.1226 · Cited by 135
The Inhibitory Effect of Calumenin on the Vitamin K-dependent γ-Carboxylation System
Wajih, N., Sane, D. C., Hutson, S. M., & Wallin, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401645200 · Cited by 134
Sconce, E. A., Khan, T. I., Mason, J. B., Noble, F., Wynne, H., & Kamali, F. (2005) · Thrombosis and Haemostasis · doi:10.1160/th04-12-0773 · Cited by 124
Harrington, D. J., Underwood, S., Morse, C., Shearer, M. J., Tuddenham, E. G. D., & Mumford, A. D. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-08-0540 · Cited by 121
Chowbay, B., Li, H., Machin, D., Cheung, Y. B., & Lee, E. J. D. (2005) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2005.02392.x · Cited by 119
The Vitamin K–Dependent Carboxylase
Berkner, K. L. (2000) · Journal of Nutrition · doi:10.1093/jn/130.8.1877 · Cited by 117
Warfarin dosing and cytochrome P450 2C9 polymorphisms
Johnson, F. B., Longtine, J. A., Kucher, N., Joffe, H. V., Xu, R., & Goldhaber, S. Z. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-02-0083 · Cited by 112
Saupe, J., Shearer, M. J., & Kohlmeier, M. (1993) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/58.2.204 · Cited by 96
Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe.
Zhang, Z., Fasco, M. J., Huang, Z., Guengerich, F. P., & Kaminsky, L. S. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06865-5 · Cited by 93
Mechanism of action of warfarin. Warfarin and metabolism of vitamin K1
Bell, R. G., Sadowski, J. A., & Matschiner, J. T. (1972) · Biochemistry · doi:10.1021/bi00760a034 · Cited by 86
Major Bleeding Complications in a Specialized Anticoagulation Service
Fanikos, J. R., Grasso-Correnti, N., Shah, R. V., Kucher, N., & Goldhaber, S. Z. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.03.104 · Cited by 79
Cytochrome P450 polymorphisms are associated with reduced warfarin dose
Freeman, B. D., Zehnbauer, B. A., McGrath, S. D., Borecki, I. B., & Buchman, T. G. (2000) · Surgery · doi:10.1067/msy.2000.107283 · Cited by 78
The current clinical practice of pharmacogenetic testing in Europe: TPMT and HER2 as case studies
Woelderink, A., Ibarreta, D., Hopkins, M. M., & Rodríguez‐Cerezo, E. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500341 · Cited by 74
Sadler, J. E. (2004) · Nature · doi:10.1038/427493a · Cited by 71
Warfarin dose related to apolipoprotein E (APOE) genotype
Kohnke, H., Sörlin, K., Granath, G., & Wadelius, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0936-3 · Cited by 68
Self-citationChan, F. W. H., Wong, R. S. M., Cheng, G. Y.-M., & You, J. H. S. (2004) · Thrombosis and Haemostasis · doi:10.1160/th04-03-0161 · Cited by 65
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose
Tai, G., Farin, F. M., Rieder, M. J., Dreisbach, A. W., Veenstra, D. L., Verlinde, C. L. M. J., & Rettie, A. E. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000162005.80857.98 · Cited by 62
Patients with an ApoE ϵ4 allele require lower doses of coumarin anticoagulants
Visser, L. E., Trienekens, P. H., Smet, P. A. G. M. D., Vulto, A. G., Albert Hofman, D., van Duijn, C. M., & Stricker, B. H. C. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200502000-00002 · Cited by 61
A comparative study of the interaction of warfarin with human α1-acid glycoprotein and human albumin
Otagiri, M., Maruyama, T., Imai, T., Suenaga, A., & Imamura, Y. (1987) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1987.tb03412.x · Cited by 44
Review of computerized decision support systems for oral anticoagulation management
Fitzmaurice, Hobbs, R. F., Delaney, B. C., Wilson, & McManus, R. J. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00858.x · Cited by 43
Extreme warfarin sensitivity in siblings associated with multiple cytochrome P450 polymorphisms
Rafii, A., McGrath, S. D., Blinder, M. A., Buchman, T. G., Zehnbauer, B. A., & Freeman, B. D. (2001) · American Journal of Hematology · doi:10.1002/ajh.1094 · Cited by 15
Ripley, T. L., Havrda, D. E., Blevins, S. M., & Culkin, D. J. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.16.1638.50949 · Cited by 10
Cited by
A Randomized Trial of Genotype-Guided Dosing of Warfarin
Pirmohamed, M., Burnside, G., Eriksson, N., Jorgensen, A. L., Toh, C. H., Nicholson, T., Kesteven, P., Christersson, C., Wahlström, B., Stafberg, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1311386 · Cited by 811
Self-citationThe largest prospective warfarin-treated cohort supports genetic forecasting
Wadelius, M., Chen, L. Y., Lindh, J. D., Eriksson, N., Ghori, M. J. R., Bumpstead, S., Holm, L., McGinnis, R., Rane, A., & Deloukas, P. (2009) · Blood · doi:10.1182/blood-2008-04-149070 · Cited by 550
Self-citationAnnunziata, F., Pinna, C., Dallavalle, S., Tamborini, L., & Pinto, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134618 · Cited by 491
Association of warfarin dose with genes involved in its action and metabolism
Wadelius, M., Chen, L. Y., Eriksson, N., Bumpstead, S., Ghori, J., Wadelius, C., Bentley, D., McGinnis, R., & Deloukas, P. (2007) · Human Genetics · doi:10.1007/s00439-006-0260-8 · Cited by 390
Self-citationWarfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups
Limdi, N. A., Wadelius, M., Cavallari, L., Eriksson, N., Crawford, D. C., Lee, M.-T. M., Chen, C.-H., Motsinger-Reif, A., Sagreiya, H., Liu, N., et al. (2010) · Blood · doi:10.1182/blood-2009-12-255992 · Cited by 370
Self-citation
Metadata
- Authors
- Wadelius, M., & Pirmohamed, M.
- Venue
- The Pharmacogenomics Journal
- Published
- 2006-09-19
- Volume
- 7
- Issue
- 2
- Pages
- 99-111
- ISSN
- 1470-269X (ISSN-L)
- 1473-1150
- OpenAlex
- W2026736116
- Cited by
- 330
- References
- 85
- FWCI
- 25.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.